Novartis shares plunge 10% after failed drug trial dims growth prospects

Novartis $NVS shares tumbled following disappointing results from a recent drug trial that cast doubt on the company's near-term growth trajectory. The setback signals challenges in the pharmaceutical giant's pipeline development.

The decline reflects investor concerns over clinical progress and revenue momentum. Analysts are reassessing earnings forecasts and product portfolio potential for the Swiss multinational. #sante #marche